Pharmacokinetic and pharmacodynamic interactions of fluvastatin and their therapeutic implications

Reviews in Contemporary Pharmacotherapy

Volumn 7, Issue 4, 1996, Pages 167-182

  Appel, Silke ^a   Dingemanse, Jasper ^b  

^a Sandoz Pharma Ltd   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000468588     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (141)

1. Ahmad S. Lovastatin. Warfarin interaction. Arch Intern Med 1990; 150: 2407.
2. Appel S, Rüfenacht T, Kalafsky G et al. Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus. Am J Cardiol 1995; 76: 29A-32A.
3. Arnadottir M, Eriksson L-O, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without cyclosporin. Nephron 1993; 65: 410-413.
4. Bach LA, Cooper ME, O'Brien RC, Jerums G. The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis. J Am Geriatr Soc 1990; 38: 10-14.
5. Barbir M, Rose M, Kushwaha S, Akl S, Mitchell A, Yacoub M. Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation. Int J Cardiol 1991; 33: 241-246.
6. Barbir M, Hunt BJ, Gallowany D et al. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting. Clin Cardiol 1994; 17: 59-64.
7. Bazzato G, Landini S, Fracasso A et al. Treatment of nephrotic syndrome hyperlipidemia with simvastatin. Curr Ther Res 1991; 50: 744-752.
8. Berland Y, Vacher Coponat H, Durand C, Baz M, Laugier R, Musso JL. Rhabdomyolysis with simvastatin use. Nephron 1991; 57: 365-366.
9. Biesenbach G, Zazgornik J. Lovastatin in the treatment of hypercholesterolemia in nephrotic syndrome due to diabetic nephropathy stage IV-V. Clin Nephrol 1992; 37: 274-279.
10. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase. Am J Cardiol 1994; 73: 3D-11D.
11. Brunner FP, Broyer M, Brynger H et al. Survival on renal replacement therapy. Data from the EDTA registery. Nephrol Dial Transplant 1988; 2: 109-122.
12. Catalano P. Pravastatin safety: an overview. In: Wood C, ed. Lipid management: pravastatin and the differential pharmacology of HMG-CoA reductase inhibitors. Royal Society of Medicine Round Table Series No 16. Oxford: Alden Press 1990; 16: 26-31.
13. Cheng H, Rogers JD, Sweany AE et al. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm Res 1992; 9: 1629-1633.
14. Cheung AK, DeVault GA, Gregory MC. A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol 1993; 3: 1884-1891.
15. Contermans J, Smit JWA, Bär PR, Erkelens DW. A comparison of the effects of simvastatin and pravastatin monotherapy on muscle histology and permeability in hypercholesterolaemic patients. Br J Clin Pharmacol 1995; 39: 135-141.
16. Corpier CL, Jones PH, Suki WN et al. Rhabdomyolysis and renal injury with lovastatin use. JAMA 1988; 260: 239-241.
17. D'Agostino RB, Kannel WB, Stepanians MN, D'Agostino LC. Efficacy and tolerability of lovastatin in elderly hypercholesterolemic patients. Clin Ther 1992; 14: 68-76.
18. Dain JG, Nicoletti J, Troendle AJ. Assessment of the inhibitary activity of metabolites of XU 62-320 at steady state in human plasma toward HMG CoA reductase. Data on file 1990.
19. pA-I. Am J Cardiol 1994; 96 (Suppl 6A): 32-36.
20. Davignon J, Montigny M, Dufour R. HMG-CoA reductase inhibitors: a look back and a look ahead. Can J Cardiol 1992; 8: 843-864.
21. Davignon J, Roederer G, Montigny M et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 1994; 73: 339-345.
22. Deslypere JP, Vermeulen A. Rhabdomyolysis and simvastatin. Ann Intern Med 1991; 114: 342.
23. Dettinger HM, Kolle EU, Karara AH, Ackermann W, Lundqvist T, Pacha W. A drug-drug interaction study with XU 62-320 and bezafibrate in healthy volunteers. Data on file 1991.
24. Dettinger HM, Smith HT, Kovarik J, Lundqvist T, Koelle EU. Assessment of the inhibitory activity of metabolites of XU 62-320 at steady-state in human plasma toward HMG-CoA reductase. Data on file 1994.
25. Duggan DE, Vickers S. Physiological disposition of HMG-CoA reductase inhibitors. Drug Metab Rev 1990; 22: 333-362.
26. Dujovne CA, Davidson MH. Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy. Am J Med 1994; 96 (Suppl 6A): 37-40.
27. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988; 318: 47-48.
28. Eliav O, Schurr D, Pfister P, Friedlander Y, Leitersdorf E. High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia. Am J Cardiol 1995; 76: 76A-79A.
29. Engstrom RG, Weinstein DB, Kathawala FG et al. XU 62-320: Hypolipoproteinemic effects of a potent HMG-CoA reductase inhibitor. 8th Int Symp Atherosclerosis, Rome, October 9-13, 1988: 230.
30. Erkelens DW. Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia. Cardiology 1990; 77 (Suppl 4): 33-38.
31. Erkelens DW, Baggen MGA, Van Doormaal JJ, Kettner M, Koningsberger JC, Mol MJTM. Clinical experience with simvastatin compared with cholestyramine. Drugs 1988; 36 (Suppl 3): 87-92.
32. Farmer JA, Gotto AM. Antihyperlipidaemic agents. Drug interactions of clinical significance. Drug Safety 1994; 11: 301-309.
33. Farrer M, Winocour PH, Evans K et al. Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures. Diabetes Res Clin Pract 1994; 23: 111-119.
34. Fischer V, Baldeck P. Fluvastatin (XU 62-320). Effect on CYP2C and on the metabolism of oral antidiabetics. Data on file 1994.
35. Fontbonne A, Eschwege E, Cambien F et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32: 300-304.
36. Garg A. Lipid-lowering therapy and macrovascular disease in diabetes mellitus. Diabetes 1992; 41 (Suppl 2): 111-115.
37. Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 81-86.
38. Garg A, Grundy SM. Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM. Diabetes 1989; 38: 364-372.
39. Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care 1990; 13: 153-169.
40. Garnett WR, Venitz J, Wilkens R, Dimenna G. Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin. Am J Med 1994; 96 (Suppl 6A): 84-86.
41. Gaw A, Wosornu D. Simvastatin during warfarin therapy in hyperlipoproteinaemia. Lancet 1992; 340: 979-980.
42. Glueck CJ, Oakes N, Speirs J, Tracy T, Lang J. Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol 1992; 70: 1-9.
43. Goldberg RB, Roth D. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant recipients receiving cyclosporine. Am J Cardiol 1995; 76: 107A-109A.
44. Goldberg R, La Belle P, Zupkis R, Ronca P. Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus. Am J Cardiol 1990; 66: 16B-21B.
45. Gonzalez FJ. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 1992; 13: 346-352.
46. Grundy SM, Vega GL, Garg A. Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in various forms of dyslipidemia. Am J Cardiol 1990; 66: 31B-38B.
47. Guengerich FP. Bioactivation and detoxication of toxic carcinogenic chemicals. Drug Metab Disp 1993; 21: 1-6.
48. Gwynne JT, Appel S, Kumle A, Kirkesseli S, Merdjan H, Kalafsky G. Pharmacokinetic/pharmacodynamic interaction study with fluvastatin and warfarin in healthy male subjects. Data on file 1994.
49. Hagen E, Istad H, Ose L et al. Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine. Eur J Clin Pharmacol 1994; 46: 445-449.
50. Halstenson CE, Triscari J, DeVault AR, Shapiro B, Keane W, Pan H. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol 1992; 32: 124-132.
51. Hansten PD, Horn JR. Pharmacokinetic drug interactions. Mechanisms and clinical characteristics. Drug interactions & updates quarterly. Spokane WA: Applied Therapeutics Inc., 1994: 13.
52. Hartmann K, Kuhn M, Gartmann J. Simvastatine et pravastatine: cex nouveaux hypolipidémiants, inhibiteurs de la synthèse du cholestérol, sous la loupe du CSPV. Bull Med Suisses 1992; 49: 1915-1917.
53. Henwood JM, Heel RC. Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs 1988; 36: 429-454.
54. Hermans JJR, Thijssen HHW. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Pharmacol 1993; 110: 482-490.
55. Holdaas H, Hartmann A, Stenstrøm J, Dahl K, Borge M, Pfister P. Effect of fluvastatin for safely lowering atherogenic lipids in renal-transplant patients receiving cyclosporine. Am J Cardiol 1995; 76: 102A-106A.
56. Horsmans Y, Desager JP, Harvengt C. Effects of combined bezafibrate-simvastatin appraised in healthy subjects. J Clin Pharmacol 1992; 32: 422-426.
57. Hunninghake DB, Hibbard DM. Effect of lovastatin and simvastatin on hepatic oxidative drug metabolizing enzymes. 8th Int Symp Atherosclerosis, Rome, October 9-13, 1988; 390.
58. Ikeda T, Ochi H, Ohtani I et al. Comparison of the effects of small doses of probucol and pravastatin on serum lipids and apolipoproteins in nonobese, non-insulin dependent diabetes mellitus patients with hypercholesterolemia. Curr Ther Res 1992; 51: 593-599.
59. Illingworth DR. Clinical implications of new drugs for lowering plasma cholesterol concentrations. Drugs 1991; 41: 151-160.
60. Inoue Y, Kaku K, Okubo M et al. A multi-centre study of the efficacy and safety of pravastatin in hypercholesterolaemic patients with non-insulin-dependent diabetes mellitus. Curr Med Res Opin 1994; 13: 187-194.
61. Jacob BG, Möhrle W, Richter WO, Schwandt P. Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolaemia. Eur J Clin Pharmacol 1992; 42: 353-358.
62. Jacob BG, Richter WO, Schwandt P. Long-term treatment (2 years) with the HMG CoA reductase inhibitors lovastatin or pravastatin in combination with cholestyramine in patients with severe primary hypercholesterolemia. J Cardiovasc Pharmacol 1993; 22: 396-400.
63. Jacobson TA, Jokubaitis LA, Amorosa LF. Fluvastatin and niatin in hypercholesterolemia: a preliminary report on gender differences in efficacy. Am J Med 1994a; 96 (Suppl 6A): 64-68.
64. Jacobson TA, Chin MM, Fromell GJ, Jokubaitis LA, Amorosa LF. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol 1994b; 74: 149-154.
65. Jacotot B, Banga JD, Waite R, Peters TK. Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (A 156-week multicenter study). Am J Cardiol 1995; 76: 41A-46A.
66. Jungnickel PW, Cantral KA, Maloley PA. Pravastatin: a new drug for the treatment of hypercholesterolemia. Clin Pharm 1992; 11: 677-689.
67. Kantner TR. HMG CoA reductase inhibitors for treatment of hyperlipidemia. Am Fam Physician 1993; 47: 1623-1627.
68. Kathawala FG. HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia. Med Res Rev 1991; 11: 121-146.
69. Kjaer K, Hangaard J, Petersen NE, Hagen C. Effect of simvastatin in patients with Type I (insulin-dependent) diabetes mellitus and hypercholesterolemia. Acta Endocrinol 1992; 126: 229-232.
70. Knopp RH, Frohlich J, Jokubaitis LA, Dawson K, Broyles FE, Gomez-Coronado D. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia. Am J Med 1994; 96 (Suppl 6A): 69-78.
71. Kobashigawa JA, Murphy FL, Stevenson LW et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990; 82 (Suppl 5): IV281-IV283.
72. Kuhlmann J. Drug interaction studies during drug development: which, when, how? Int J Clin Pharmacol Ther ToxicoI 1994; 32: 305-311.
73. TB (CYP2C subfamily): The common site of NSAIDs oxidation by human liver. 13th Eur Workshop on Drug Metabolism. Bergamo, Italy, 21-25 September, 1992.
74. Leitersdorf E, Muratti EN, Eliav O et al. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination. Am J Med 1994; 96: 401-407.
75. Leitersdorf E, Muratti EN, Eliav O, Peters TK. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. Am J Cardiol 1995; 76: 84A-88A.
76. Li PKT, Mak TWL, Wang AYM et al. The interaction of fluvastatin and cyclosporin A in renal-transplant patients. Int J Clin Pharmacol Ther 1995; 33: 246-248.
77. Lintott CJ, Scott RS, Nye ER, Robertson ML, Sutherland WHF. The hypolipidaemic effects of pravastatin (CS-514) alone and in combination with bezafibrate or acipimox in patients with primary hypercholesterolaemia. Diabetes Nutr Metab 1991; 4: 117-122.
78. Lintott CJ, Scott RS, Bremer JM, Shand BI. Fluvastatin for dyslipoproteinemia with or without concomitant chronic renal insufficiency. Am J Cardiol 1995; 76: 97A-101A.
79. Marais GE, Larson KK. Rhabdomyolysis and acute renal failure by combination lovastatin and gemfibrozil therapy. Ann Intern Med 1990; 112: 228-230.
80. Martini S, Gabelli C, Pagano GF. Efficacy and safety of simvastatin for the treatment of hypercholesterolemia in patients with and without type II diabetes. Curr Ther Res 1992; 52: 281-290.
81. Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 1993; 24: 195-202.
82. Mauro VF, MacDonald JL. Simvastatin: a review of its pharmacology and clinical use. DICP, Ann Pharmacother 1991; 25: 257-264.
83. McKenney JM. Lovastatin: a new cholesterol-lowering agent. Clin Pharm 1988; 7: 21-36.
84. Merck and Company. Mevacor® (lovastatin). Physicians' Desk Reference. Montvale, NJ: Medical Economics Data Production Company, 1993a.
85. Merck and Company. Zocor® (simvastatin). Physicians' Desk Reference. Montvale, NJ: Medical Economics Data Production Company, 1993b.
86. Miccoli R, Bertolotto A, Giovannitti MG et al. Simvastatin for lowering cholesterol levels in non-insulin-dependent mellitus and in primary hypercholesterolemia. Curr Ther Res 1992; 51: 66-74.
87. Mol MJTM, Stalenhoef AFH. HMG CoA reductase inhibitors. Curr Opin Lipidol 1993; 4: 41-48.
88. Müller H-J, Gundert-Remy U. The regulatory view on drug-drug interactions. Int J Clin Pharmacol Ther Toxicol 1994; 32: 269-273.
89. Newman TJ, Kassler-Taub KB, Gelarden RT et al. Safety of pravastatin in long-term clinical trials conducted in the United States. J Drug Dev 1990; 3 (Suppl 2): 275-281.
90. Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med 1988; 318: 46-47.
91. O'Brien RC, Simons LA, Clifton P et al. Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolaemia. Med J Aust 1990; 152: 480-483.
92. Owens D, Stinson J, Collins P, Johnson A, Tomkin GH. Improvement in the regulation of cellular cholesterologenesis in diabetes: the effect of reduction in serum cholesterol by simvastatin. Diabetic Med 1991; 8: 151-156.
93. Pan HY. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. Eur J Clin Pharmacol 1991; 40 (Suppl 1): 15-18.
94. Pan H, Gourzis J, Kassalow L, Whigan D, Waclawski A, Martynowicz H. Pharmacokinetics of pravastatin, an HMG-CoA reductase inhibitor in healthy female subjects. J Clin Pharmacol 1988; 28: 908-959.
95. Pan H, Funke P, Waclawski A, Willard D. Comparative pharmacokinetics of pravastatin, an HMG CoA reductase inhibitor, in healthy elderly and young male subjects. J Clin Pharmacol 1989a; 29: 832-862.
96. Pan HY, Swanson BN, DeVault AR, Willard D, Bresica D. Antipyrine elimination is not affected by chronic administration of pravastatin (SQ 31000), a tissue-selective HMG CoA reductase inhibitor. Clin Res 1989b; 36: 368A.
97. Pan HY, DeVault AR, Swites BJ, Willard D, Brescia D. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 1990; 48: 201-207.
98. Pan HY, Triscari J, DeVault AR et al. Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. Br J Clin Pharmacol 1991; 31: 665-670.
99. Pan HY, DeVault AR, Brescia D et al. Effects of food on pravastatin pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther Toxicol 1993; 31: 291-294.
100. Paolisso G, Sgambato S, De Riu S et al. Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics. Eur J Clin Pharmacol 1991; 40: 27-31.
101. Peters TK, Mehra M, Muratti EN. Efficacy and safety of fluvastatin in hypertensive patients. An analysis of a clinical trial database. Am J Hypertens 1993a; 6: 340S-345S.
102. Peters TK, Jewitt-Harris J, Mehra M, Muratti EN. Safety and tolerability of fluvastatin with concomitant use of antihypertensive agents. An analysis of a clinical trial database. Am J Hypertens 1993b; 6: 346S-352S.
103. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71-75.
104. Pirsch JD, D'Alessandro AM, Sollinger HW et al. Hyperlipidemia and transplantation: etiologic factors and therapy. J Am Soc Nephrol 1992; 2 (Suppl 3): 238-242.
105. Quion JAV, Jones PH. Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 1994; 27: 94-103.
106. Rabelink AJ, Erkelens DW, Hene RJ, Joies JA, Koomans HA. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet 1988; 2: 1335-1338.
107. Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 1988; 109: 597-598.
108. Regazzi MB, Iacona I, Campana C et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993; 25: 2732-2734.
109. Relling MV, Aoyama T, Gonzalez FJ, Meyer UA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 1990; 252: 442-447.
110. Rettie AE, Korzekwa KR, Kunze KL et al. Hydroxylation of warfarin by human cDNA-expressed cytochorome P450: a role for P4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992; 5: 54-59.
111. Sandoz Pharma Ltd. Lescol® (fluvastatin sodium). Physicians' Desk Reference. Montvale, NJ: Medical Economics Data Production Company, 1994.
112. Smit JWA, Wijnne HA, Schobben F, Sitsen A, De Bruin TWA, Erkelens DW. Effects of alcohol consumption on pharmacokinetics, efficacy and safety of fluvastatin. Am J Cardiol 1995a; 76: 89A-96A.
113. Smit JWA, Jansen GH, De Bruin JWA, Erkelens DW. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil alone and in combination does not induce muscle damage. Am J Cardiol 1995b; 76: 126A-128A.
114. Smith HT, Jokubaitis LA, Troendle AJ, Hwang DS, Robinson WT. Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens 1993; 6: 375S-382S.
115. Smith PF, Eydelloth RS, Grossman SJ et al. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 1991; 257: 1225-1235.
116. Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995; 76: 80A-83A.
117. Sprecher DL, Abrams J, Allen JW et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 1994; 120: 537-543.
118. Squibb. Pravachol® (pravastatin sodium). Physicians' Desk Reference. Montvale, NJ: Medical Economics Data Production Company, 1994.
119. Steyn K, Weich HFH, Bonnici F et al. Simvastatin in non-insulin dependent-diabetic patients with hypercholesterolaemia. S Afr Med J 1992; 82: 402-406.
120. Tobert JA. HMG-CoA reductase inhibitors for hypercholesterolemia. N Engl J Med 1988a; 319: 1222.
121. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988b; 62: 28J-34J.
122. Tobert JA, Shear CL, Chremos AN, Mantell GE. Clinical experience with lovastatin. Am J Cardiol 1990; 65: 23F-26F.
123. Todd PA, Goa KL. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1990; 40: 583-607.
124. Torri A, Sommariva D, Maraffi F et al. Long-term effects of low-dose simvastatin in hypercholesterolemic type 2 diabetic patients. Curr Ther Res 1992; 51: 28-36.
125. Transon C, Leemann T, Dayer P. Selective in vitro P450 inhibition profile by fluvastatin indicates its potential in vivo drug interactions. Clin Pharmacol Ther 1993; 53: 188.
126. Triscari J, Swanson BN, Willard DA, Cohen AI, DeVault AR, Pan HY. Steady state serum concentrations of pravastatin and digoxin when given in combination. Br J Clin Pharmacol 1993; 36: 263-265.
127. Tse FLS, Nickerson D. Binding of fluvastatin and its enantiomers, 62-735 and 62-850, to human plasma proteins: competition with warfarin, salicylic acid, and glyburide. Data on file 1991.
128. Tse FLS, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 1992; 32: 630-638.
129. Tse FLS, Nickerson DF, Yardley WS. Binding of fluvastatin to blood cells and plasma proteins. J Pharm Sci 1993; 82: 942-947.
130. Vanhaecke J, Van Cleemput J, Lierde JV, Daenen W, DeGeest H. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 1994; 58: 42-45.
131. Veronese ME, McKenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C. Biochem Biophys Res Commun 1991; 175: 1112-1118.
132. Vyas KP, Kari PH, Pakash SR, Duggan DE. Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation of lovastatin. Drug Metab Disp 1990; 18: 218-222.
133. Walker JF. Simvastatin: the clinical profile. Am J Med 1989; 87 (Suppl 4A): 44-46.
134. Wanner C, Hörl WH, Luley CH, Wieland H. Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney Int 1991; 39: 754-760.
135. West KM, Ahuja MMS, Bennett PH et al. The role of circulating glucose and triglyceride concentrations and their interactions with other 'risk factors' as determinants of arterial disease in nine diabetic population samples from the WHO Multinational Study. Diabetes Care 1983; 6: 361-369.
136. Wiklund O, Angelin B, Bergman M et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993; 94: 13-20.
137. Wurm M. XU-62-320 (fluvastatin). Clinical results of 1116 patients. Clin Res Bull 1991; 3: 43-48.
138. Yeshurun D, Abukarshin R, Elias N et al. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination. Clin Therapeutics 1993; 15: 355-363.
139. Yoshimura N, Oka T, Okamoto M, Ohmori Y. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992; 53: 94-99.
140. Yoshino G, Kazumi T, Kasama T et al. Effect of CS-514, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on lipoprotein and apolipoprotein in plasma of hypercholesterolemic diabetics. Diabetes Res Clin Pract 1986; 2: 179-181.
141. Yoshino G, Kazumi T, Iwai M et al. Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514). Atherosclerosis 1989; 75: 67-72.